| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
In HOS cells, telomerase activation is inhibited by TMPyP4 tosylate (50μM, 96 hours) [2]. HOS cell proliferation is inhibited by 50μM TMPyP4 tosylate when applied over 48 or 96 hours [2]. In HOS, Saos-2, MG-63, and U2OS cell lines, TMPyP4 tosylate (50μM, 96 h) causes cell disinfection [2]. In K562 cells, TMPyP4 tosylate (100 μM, 24 or 48 hours) increases cell cycle factor proteins.
|
|---|---|
| ln Vivo |
In the MX-1 tumor model, TMPyP4 tosylate (10 and 20 mg/kg, ip, twice weekly) suppresses tumor growth [5]. SARS-CoV infection is reduced by TMPyP4 tosylate (15 mg/kg or 30 mg/kg, in). In hamsters, TMPyP4 tosylate (30 mg/kg, in) reached its maximum concentration 1 hour after the drug's administration, with a Cmax of 17.88 μg/mL and a half-life (T1/2) of 6.36 h[6]. In hamsters, the typical virus load is 2 [6]. ].
|
| Cell Assay |
Cell viability assay [2]
Cell Types: HOS Cell Tested Concentrations: 50 μM Incubation Duration: 48 or 96 h Experimental Results: Time-dependent inhibition Cell viability. and MAPK content[4]. Western Blot Analysis[4] Cell Types: K562 Cell Tested Concentrations: 100 µM Incubation Duration: 24 or 48 hrs (hours) Experimental Results: Increased expression of p21CIP1 protein and p57KIP2 protein. |
| Animal Protocol |
Animal/Disease Models: MX-1 breast chemotherapy adjuvant model [5]
Doses: 10 and 20 mg/kg Route of Administration: intraperitoneal (ip) injection, twice a week. Experimental Results: Inhibited tumor growth and prolonged mouse survival. Animal/Disease Models: Hamsters infected with SARS-CoV-2 [6] Doses: 15 mg/kg or 30 mg/kg Route of Administration: Started 1 hour before virus inoculation and continued until 3 days after infection Experimental Results: Average virus reduction in nasal wash , turbinates, and loads in lung tissue. |
| References |
|
| Molecular Formula |
C44H42N8.4[C7H8O3S]
|
|---|---|
| Molecular Weight |
1371.66436
|
| Exact Mass |
1362.368
|
| CAS # |
36951-72-1
|
| Appearance |
Pale purple to purple solid powder
|
| LogP |
10.083
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~25 mg/mL (~18.33 mM)
DMSO : ~10 mg/mL (~7.33 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (0.73 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (0.73 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 7.14 mg/mL (5.24 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7290 mL | 3.6452 mL | 7.2904 mL | |
| 5 mM | 0.1458 mL | 0.7290 mL | 1.4581 mL | |
| 10 mM | 0.0729 mL | 0.3645 mL | 0.7290 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
